奥替拉西 (Teysuno)

Oteracil

未知生产厂商

Oteracil is a chemotherapy agent used in combination with tegafur, cisplatin and gimeracil to treat advanced gastric cancer.

生成 AI 研报

医学正文保留数据源原文，避免将未经专业审核的机器翻译呈现为临床事实。

概览

Oteracil is a chemotherapy agent used in combination with tegafur, cisplatin and gimeracil to treat advanced gastric cancer.

作用机制

Oteracil's main role within Teysuno is to reduce the activity of 5-FU within normal gastrointestinal mucosa, and therefore reduce's gastrointestinal toxicity . It functions by blocking the enzyme orotate phosphoribosyltransferase (OPRT), which is involved in the production of 5-FU.

适应症

Oteracil is used as an adjunct to antineoplastic therapy. When used within the product Teysuno, oteracil is indicated for the treatment of adults with advanced gastric (stomach) cancer when given in combination with cisplatin.

专利

每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。

Antitumor effect potentiator and antitumor agent
US 2006116345 A1申请人: TAIHO PHARMACEUTICAL CO LTD优先权: 2003
CN
US
4 件公开
Antitumor Effect Potentiator, Antitumor Preparation, and Method for Treating Cancer
US 2008306073 A1申请人: KOIZUMI KATSUHISA优先权: 2004
CN
US
3 件公开
Agent for enhancing anti-tumor effect comprising oxaliplatin liposome preparation, and anti-tumor agent comprising the liposome preparation
US 8940327 B2申请人: ISHIDA TATSUHIRO优先权: 2008
CN
US
3 件公开
Antitumor agent, kit and method of treating cancer
US 8410096 B2申请人: PARK SUNG HWA优先权: 2008
US
2 件公开
Method for predicting therapeutic efficacy of chemotherapy on non-small-cell lung cancer
US 8598188 B2申请人: NAKAGAWA KAZUHIKO优先权: 2009
US
2 件公开
Method for predicting therapeutic effect of chemotherapy on renal cell cancer
US 8992947 B2申请人: AKAZA HIDEYUKI优先权: 2009
US
2 件公开
Method for prediction of therapeutic effect of chemotherapy employing expression level of dihydropyrimidine dehydrogenase gene as measure
US 8697681 B2申请人: OKA TOSHINORI优先权: 2009
US
2 件公开
Method for selecting chemotherapy for gastric cancer patient using combination drug of tegafur, gimeracil and oteracil potassium and EGFR inhibitor
US 9345767 B2申请人: KOBUNAI TAKASHI优先权: 2011
US
2 件公开
Orally disintegrating preparation containing tegafur, gimeracil and oteracil potassium
CN 116270509 A申请人: FIRST AFFILIATED HOSPITAL ZHENGZHOU UNIV优先权: 2022
CN
2 件公开
Disintegration piece taken through oral cavity containing Gimeracil and Oteracil Potassium with fluorine being added
CN 1660105 A申请人: LUNAN PHARM CO LTD优先权: 2004
CN

药物

奥替拉西 (Teysuno)

概览

作用机制

适应症

相关疾病

专利